The Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis and Progressive Fibrosing Interstitial Lung Diseases: A Real-World Study.
Paolo CameliValerio AlonziMiriana d'AlessandroLaura BergantiniElena PordonMarco GuerrieriRosa Metella RefiniPiersante SestiniElena BargagliPublished in: Biomedicines (2022)
our research studies the effectiveness and safety of nintedanib in reducing functional disease progression of IPF and PF-ILD. FPF appeared to be less responsive to nintedanib, even though no differences were observed in terms of survival.